{"id":55173,"date":"2023-03-24T13:07:01","date_gmt":"2023-03-24T12:07:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/"},"modified":"2023-03-24T13:07:01","modified_gmt":"2023-03-24T12:07:01","slug":"bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/","title":{"rendered":"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023"},"content":{"rendered":"
\n

\nConference Call scheduled on April 3, 2023, at 9 a.m. Eastern time<\/i>\n<\/p>\n

SAN ANTONIO–(BUSINESS WIRE)–#CyPathLung<\/a>—bioAffinity Technologies<\/b><\/a>, Inc. (NASDAQ: BIAF; BIAFW)<\/b> today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, 2023, at 9:00 a.m. Eastern time to discuss those results and answer questions.\n<\/p>\n

<\/a><\/p>\n\n\n\n\n\n\n\n
\n

\nEvent:<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n

\nbioAffinity Technologies Fourth Quarter 2022 Financial Results\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nDate:<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n

\nMonday, April 3, 2023\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nTime:<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n

\n9:00 a.m. EDT\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nToll Free:<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n

\n1-877-270-2148\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nInternational:<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n

\n1-412-902-6510\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWebcast:<\/b>\n<\/p>\n<\/td>\n

\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n

\nWebcast link<\/a>\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nA replay of the event will be available for 90 days at the webcast link above, which can also be found in the Investor Relations section of bioAffinity\u2019s website at ir.bioaffinitytech.com<\/a>.\n<\/p>\n

\nAbout bioAffinity Technologies, Inc.<\/b>\n<\/p>\n

\nbioAffinity Technologies, Inc. addresses the need for non-invasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. The Company\u2019s first product, CyPath\u00ae Lung<\/a>, is a non-invasive test that has shown high sensitivity and specificity for the detection of early-stage lung cancer. CyPath\u00ae Lung is marketed as a Laboratory Developed Test (LDT) by Precision Pathology Services<\/a>. OncoSelect Therapeutics, LLC, a subsidiary of bioAffinity Technologies, is advancing its discoveries shown in vitro to kill cancer cells without harm to normal cells. Research and optimization of the Company\u2019s platform technologies are conducted in its laboratories at The University of Texas at San Antonio. For more information, visit www.bioaffinitytech.com<\/a>.\n<\/p>\n

\nForward-Looking Statements<\/b>\n<\/p>\n

\nThis press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company\u2019s offering of common shares. Forward-looking statements can be identified by words such as \u201cbelieves,\u201d \u201cexpects,\u201d \u201cestimates,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cplans,\u201d \u201cwill\u201d and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nbioAffinity Technologies<\/b>
Julie Anne Overton
\n
Director of Communications
\n
jao@bioaffinitytech.com<\/a>\n<\/p>\n

\nLHA Investor Relations<\/b>
Tirth T. Patel
\n
tpatel@lhai.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time SAN ANTONIO–(BUSINESS WIRE)–#CyPathLung—bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55173","6":"format-standard","7":"category-industry"},"yoast_head":"\nbioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time SAN ANTONIO–(BUSINESS WIRE)–#CyPathLung—bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-24T12:07:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230324005073\/en\/797416\/21\/bioAfinity_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023\",\"datePublished\":\"2023-03-24T12:07:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/\"},\"wordCount\":392,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005073\\\/en\\\/797416\\\/21\\\/bioAfinity_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/\",\"name\":\"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005073\\\/en\\\/797416\\\/21\\\/bioAfinity_logo.jpg\",\"datePublished\":\"2023-03-24T12:07:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005073\\\/en\\\/797416\\\/21\\\/bioAfinity_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230324005073\\\/en\\\/797416\\\/21\\\/bioAfinity_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/","og_locale":"en_US","og_type":"article","og_title":"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 - Pharma Trend","og_description":"Conference Call scheduled on April 3, 2023, at 9 a.m. Eastern time SAN ANTONIO–(BUSINESS WIRE)–#CyPathLung—bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close. The Company will host a conference call on Monday, April 3, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-03-24T12:07:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230324005073\/en\/797416\/21\/bioAfinity_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023","datePublished":"2023-03-24T12:07:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/"},"wordCount":392,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230324005073\/en\/797416\/21\/bioAfinity_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/","url":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/","name":"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230324005073\/en\/797416\/21\/bioAfinity_logo.jpg","datePublished":"2023-03-24T12:07:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230324005073\/en\/797416\/21\/bioAfinity_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230324005073\/en\/797416\/21\/bioAfinity_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/bioaffinity-technologies-to-report-fourth-quarter-2022-financial-results-on-march-31-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"bioAffinity Technologies to Report Fourth Quarter 2022 Financial Results on March 31, 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55173","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55173"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55173\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55173"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55173"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55173"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}